Home > Formulary : Adult > Recent Decisions > 2016 >
Decisions 29th November 2016
At the meeting that took place on 29th November, the following decisions were agreed:
New Drug Requests
Approved
Feraccru®
- Approved for inclusion on the formulary for 12 months. Audit data to be reviewed after this period
Metvix®
- Approved for inclusion on the formulary if Photodynamic Therapy is approved
Nexobrid®
- Approved to be added to the formulary on confirmation of directorate funding available
Jaydess®
- To be added to the formulary as an alternative for patients that are unable to use Mirena®
Not Approved
Guanfacine
- More evidence required
Other
Adrenaline pen review
- 3 brands to be added
Adjuvant bisphosphonates in Breast Cancer
- Ibandronate to be added when SCP in available
Fostair Nexthaler®
- To be added for COPD
Shared Care Protocols/TLS Change in Status
Rufinamide
- Updated SCP approved
Riluzole
- Update SCP approved
Azathioprine
- Dermatology oral mucosal updates approved